457 / 1068
Prognostic Significance of CRM involvement after
Chemo-Radiotherapy for LARC
CRM 2yr
LR
2yr
OS
5y
OS
5yr
DFS
5yr LR
free
survival
5yr DM
free
survival
Gosens et al
2007
n = 201 cT3/T4
Neg 8% 80%
Pos
43%* 58%*
Rullier et al 2010
n = 292 uT3/T4
Neg
80%
Pos
30%*
Kim et al 2009
n = 420 cT3/T4
Neg
78%
Pos
44%*
Trakarnsanga et
al
2013
n = 563 cT3/T4
> 1mm
98 %
< 1mm
66 %
> 2mm
78 %
< 2mm
41 %*
* = significant in multivariate analysis